Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents
1Adis, a Wolters Kluwer Business, Auckland, NZ. demail@adis.co.nz
CNS Drugs
|March 24, 2011
Summary
Methylphenidate transdermal system effectively treats attention-deficit hyperactivity disorder (ADHD) in adolescents. Continuous delivery of medication significantly reduced ADHD symptoms with good tolerability over a 7-week trial and a 6-month extension study.
Area of Science:
- Pharmacology
- Neuroscience
- Pediatric Medicine
Background:
- Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in adolescents.
- Methylphenidate is a widely prescribed stimulant medication for ADHD treatment.
- Transdermal drug delivery systems offer continuous medication release for improved therapeutic outcomes.
Purpose of the Study:
- To evaluate the efficacy and tolerability of a methylphenidate transdermal system in adolescents with ADHD.
- To assess the long-term effectiveness of the methylphenidate transdermal system through an extension study.
Main Methods:
- A randomized, double-blind, multicentre, 7-week core trial.
- Adolescents aged 13-17 years with ADHD received methylphenidate transdermal system (10-30 mg) or placebo.
- An open-label extension study of approximately 6 months duration followed the core trial.
Main Results:
- The methylphenidate transdermal system significantly reduced the mean ADHD-Rating Scale-IV (ADHD-RS-IV) total score compared to placebo in the core trial.
- Continuous treatment with the methylphenidate transdermal system led to a significant reduction in ADHD-RS-IV scores from the start of the core trial to the end of the extension study.
- The treatment was generally well tolerated, with most adverse events being mild to moderate in severity.
Conclusions:
- The methylphenidate transdermal system is an effective treatment for ADHD in adolescents.
- Continuous delivery via the transdermal system provides sustained symptom control.
- The methylphenidate transdermal system demonstrates a favorable safety profile for long-term use in this population.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...